C/o Equatorial Business Group
Saris, Debrezeit Road
PO BOX 8964
Tel: +251 11 4 42 2164/6
We are doing this by developing innovative products and improving access to healthcare for patients around the world.
GSK has a new strategy in Africa that aims to make targeted investments of up to £130 million in Africa over the next five years, creating at least 500 jobs and contributing to the development of home-grown capabilities and skills in Africa. This builds on GSK’s existing business base in sub-Saharan Africa.
GSK will invest £25 million to create the world’s first R&D Open Lab for non-communicable diseases (NCDs) in Africa. It will establish up to 25 academic Chairs at local African universities to ensure sustainability and local input.
GSK will also:
Develop domestic manufacturing capacity and invest up to £100 million to expand its existing manufacturing capability in Nigeria and Kenya and up to five new factories in Africa.
Optimise our portfolio of medicines for NCDs to increase the registration of medicines and vaccines in its existing portfolio that were not already available.
Increase our support for community health worker training, in recognition of the vital role they play in delivering basic healthcare to many communities.
In 2013 GSK:
Achieved a major milestone in the development of our malaria vaccine candidate.
Invested £3.4 billon in global research and development for innovative medicines, vaccines and consumer products.
Delivery of 46.8 million vaccine doses to the GAVI Alliance at affordable prices to protect children from pneumococcal diseases, rotavirus gastroenteritis and cervical cancer.
Donated our four billionth albendazole tablet to support efforts to eliminate lymphatic filariasis.
Reinvested £5.1 million of our profits in Least Developed Countries through our 20% reinvestment programme.
“Now is the moment for business to play a more active role in contributing to a more prosperous future in Africa. Investing in infrastructure, building skills and capability to unlock human potential and create jobs. Our long-term goal is to equip Africa to discover, develop and produce the medicines required for Africa.”
Sir Andrew Witty, CEO, GSK